Please use this link to access this publication. ABSTRACT A unifying mechanistic cause for amyotrophic lateral sclerosis (ALS) remains uncertain. Multiple pathophysiological processes appear to occur simultaneously. Cannabinoids, including delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and others found in cannabis, and cannabis extracts (CEs), appear to have activity in these pathogenic pathways, which have led to increasing interest in cannabinoids as therapeutic agents for ALS. The use of cannabinoids as a treatment strategy is substantiated by preclinical evidence suggesting a role for the endocannabinoid system (ECS) in ALS and other neurodegenerative disorders. Preclinical data indicate that cannabis and CEs have powerful antioxidative, anti-inflammatory, and...

Please use this link to access this publication. Abstract Purpose Peripheral neuropathies are commonly occurring conditions that are chronic and debilitating for patients. Established nonsurgical treatments have yielded mixed and patient-dependent results. Although cannabinoids have demonstrated efficacy as a treatment for central neuropathic pain, the therapeutic potential of cannabis-based medications for the management of peripheral neuropathic pain caused by nerve injury, trauma, and other noncompressive etiologies has yet to be definitively established. This study aims to determine whether cannabinoids are a potentially effective treatment for pain and symptoms associated with peripheral neuropathy. Methods A systematic search was conducted by two independent reviewers across PubMed,...

Please use this link to access this publication. Abstract in English, French Cannabis is one of the world's most widely consumed illicit substances. In addition to being widely available, its potency has increased up to 100-fold over the last 25 years. In parallel with these plant breeding efforts, artificial products called synthetic cannabinoids (SC) have been developed in laboratories. They are more potent and dangerous than natural cannabis. This article focuses on the risks associated with SC use, their treatment, and screening from the perspective of emergency or primary care physicians.

Abstract Distinguishing between cannabinoid hyperemesis syndrome and cyclic vomiting syndrome (CVS) in patients with cyclical vomiting and heavy cannabinoid use is a significant diagnostic challenge. A critical consideration is catamenial CVS, a subtype of CVS in which vomiting episodes are closely linked to the menstrual cycle. This pattern is frequently overlooked in cannabinoid users due to the overlapping symptomatology of both conditions. However, identifying a menstrual association with vomiting episodes is crucial for diagnosing catamenial CVS because hormonal contraceptive therapy is an effective treatment. We present 2 adolescent cases of cyclical vomiting with cannabis use, where further clinical investigation revealed the menstrual cycle as...

Abstract Background: Cannabinoid hyperemesis syndrome (CHS) is a condition characterized by cyclic abdominal pain, vomiting, and nausea, primarily affecting adolescents and adults with a history of chronic cannabis use. The diagnosis of CHS is clinical, with symptom resolution upon cannabis cessation considered pathognomonic. The overlap of CHS symptoms with other conditions complicates the differential diagnosis, particularly in emergency settings. Case Presentation: We report an unusual case of a 28-year-old man admitted to the Emergency Department of Rovereto (Italy) with limb paresthesia and agitation. Initial evaluation revealed indirect clinical signs of hypocalcemia, and QTc prolongation and severe hypokalemia on electrocardiogram. The arterial blood gas analysis suggested mixed...

Please use this link to access this publication. Abstract Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition characterized by recurrent episodes of nausea, vomiting, and abdominal pain in chronic cannabis users. Despite the increasing legalization and widespread use of cannabis, CHS remains underdiagnosed, often leading to unnecessary diagnostic tests and ineffective treatments. The syndrome is marked by symptom relief through hot baths, a behavioral pattern that can aid in its identification. We report a case of a 29-year-old male with a five-year history of recurrent vomiting and significant weight loss. The patient had multiple emergency department visits and was misdiagnosed with anxiety disorder due to...

Please use this link to access this publication. Abstract Cannabinoid hyperemesis syndrome (CHS) is an emerging disorder in chronic cannabis users, characterized by recurrent nausea, vomiting, severe abdominal pain, and compulsive hot bathing. We report a case of CHS complicated by profound lactic acidosis (lactate 6.1 mmol/L), highlighting this metabolic derangement as a secondary effect of severe dehydration and physiological stress from intractable vomiting and pain. Our case underscores the importance of early recognition of CHS even when abdominal pain predominates, aggressive fluid resuscitation, and targeted therapies including haloperidol and capsaicin. We also review current evidence on CHS pathophysiology, diagnostic criteria, and management strategies, alongside the increasing prevalence...

Abstract Background Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized condition linked to chronic cannabis use, yet it remains frequently overlooked in clinical practice. The syndrome is characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. With the rising prevalence of cannabis use following its legalization, the incidence of CHS has surged, presenting a significant challenge in both diagnosis and management within primary healthcare settings. Understanding the epidemiology, risk factors, and potential long-term sequelae of CHS is crucial for timely identification and intervention. This case report highlights the challenge of diagnosis and management of...

Please use this link to access this publication. ABSTRACT Objective This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research. Methods Participants were either not using cannabis, using cannabis with THC, or using cannabis with CBD and were assessed at baseline, 2 weeks, and 4-weeks following ad libitum use of a legal market cannabis product that was randomly assigned to them. Primary outcomes included scores on the Depression Anxiety Stress (DASS) Scale...

Please use this link to access this publication. Abstract A six-year-old boy presented to the pediatric emergency department following an accidental ingestion of a synthetic cannabinoid. The child ingested an edible product containing tetrahydrocannabinol (THC) and presented with lethargy, altered mental status, and increased muscle tone. The airway was protected, and the patient was breathing spontaneously. Initial assessment included a thorough history provided by the caregivers, which confirmed ingestion of cannabinoid gummies approximately two hours prior to presentation. An electrocardiogram demonstrated sinus tachycardia with a prolonged QTc. Toxicology screening was presumed positive for cannabinoids. Therapeutic management focused on supportive care. The patient was admitted...